Moderna Competitors and Similar CompaniesClear all
Moderna's competitors and similar companies include CureVac, Regulus Therapeutics, Celyad and Sarepta Therapeutics.
 Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. |  Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. |  Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. | ||
Founding Date | Founding Date 2010 | Founding Date 2000 | Founding Date 2007 | Founding Date 2007 | Founding Date 1980 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations San Diego, US HQ | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | |
Employees | Employees 5,60044% increase | Employees 999 | Employees 2462% decrease | Employees 17 | Employees 1,31413% increase |
Valuation ($) | Valuation ($) 21.2 b | Valuation ($) 648.3 m | Valuation ($) 105.4 m | Valuation ($) 11.8 m | Valuation ($) 12.4 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $6.8b (FY, 2023) | Revenue (est.) €53.8m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) €102k (FY, 2023) | Revenue (est.) $1.2b (FY, 2023) |
Cost of goods | Cost of goods $4.7b (FY, 2023) | Cost of goods €64.3m (FY, 2023) | Cost of goods N/A | Cost of goods €69k (FY, 2023) | Cost of goods $150.3m (FY, 2023) |
Gross profit | Gross profit $2.2b (FY, 2023) | Gross profit (€2.6m) (FY, 2023) | Gross profit N/A | Gross profit €1.4m (FY, 2023) | Gross profit $1.1b (FY, 2023) |
Net income | Net income ($4.7b) (FY, 2023) | Net income (€260.2m) (FY, 2023) | Net income ($30m) (FY, 2023) | Net income (€8.4m) (FY, 2023) | Net income ($536m) (FY, 2023) |
Operating ⚠ | |||||
Patent Applications | Patent Applications 430 (FY, 2021) | Patent Applications 500 (Mar, 2020) | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A |
Patents Issued | Patents Issued 270 (FY, 2020) | Patents Issued 233 (May, 2020) | Patents Issued 300 (FY, 2016) | Patents Issued N/A | Patents Issued N/A |
Funding | |||||
Total funding raised | Total funding raised $ 1.8b | Total funding raised $ 1.1b | Total funding raised $ 10m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
CureVac
HQ
Tübingen, DE
Employees
999
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View companyRegulus Therapeutics
HQ
San Diego, US
Employees
24
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
View companyCelyad
HQ
Mont-Saint-Guibert, BE
Employees
17
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
View companySarepta Therapeutics
HQ
Cambridge, US
Employees
1,314↑ 13% increase
Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.
View company